New Zealand markets closed

G1 Therapeutics, Inc. (GTHX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
13.06-0.04 (-0.31%)
At close: 04:00PM EDT
12.75 -0.31 (-2.37%)
After hours: 07:53PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close13.10
Open13.08
Bid0.00 x 1100
Ask0.00 x 800
Day's range12.36 - 13.35
52-week range3.84 - 16.65
Volume761,740
Avg. volume1,287,543
Market cap558.273M
Beta (5Y monthly)2.20
PE ratio (TTM)N/A
EPS (TTM)-4.03
Earnings date01 Nov 2022 - 07 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est34.71
  • Zacks

    Can G1 Therapeutics (GTHX) Climb 150% to Reach the Level Wall Street Analysts Expect?

    The mean of analysts' price targets for G1 Therapeutics (GTHX) points to a 149.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

  • Motley Fool

    G1 Therapeutics, Inc. (GTHX) Q2 2022 Earnings Call Transcript

    Good morning, everyone, and welcome to the G1 conference call to discuss our second quarter '22 financial results and business update. The press release on these financial results was issued this morning and can be found in the news section of our corporate website, g1therapeutics.com. On this morning's call, the team will provide a business overview of the second quarter of '22, including an update on our clinical programs and our commercial progress in that period with Cosela, which is approved and commercially available to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum etoposide containing regimen or topotecan containing regimen for extensive-stage small cell lung cancer or ES-SCLC.

  • Zacks

    G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates

    G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 11.54% and 17.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?